Adjuvant therapy for breast cancer.
Different aspects of adjuvant therapy in breast cancer have been noteworthy in the past year. Evaluation of long-term results with nonspecific immunostimulatory agents in conjunction with adjuvant chemotherapy or tamoxifen have failed to show therapeutic benefit. Studies have also focused on whether tamoxifen represents an alternative to chemotherapy alone, or is more effective in combination with chemotherapy or radiation therapy.
Kaufmann
M
M
University Hospital, Heidelberg, FRG.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D013629:Tamoxifen / Q000627:therapeutic use; D013997:Time Factors
D000276:Adjuvants, Immunologic; D013629:Tamoxifen